Prednisolone | Placebo | |
---|---|---|
Week 4 | ||
Patients | 156 | 150 |
Haematuria only* | 8 (6%) | 4 (3%) |
Proteinuria only† | 22 (15%) | 14 (10%) |
Haematuria+proteinuria† | 16 (11%) | 10 (7%) |
Haematuria or proteinuria* | 47 (33%) | 29 (22%) |
Month 3 | ||
Patients | 146 | 150 |
Haematuria only‡ | 8 (6%) | 10 (7%) |
Proteinuria only§ | 21 (16%) | 20 (14%) |
Haematuria+proteinuria§ | 10 (7%) | 9 (6%) |
Haematuria or proteinuria‡ | 42 (31%) | 40 (28%) |
Month 12 | ||
Patients | 150 | 146 |
Haematuria only¶ | 7 (5%) | 5 (4%) |
Proteinuria only** | 25 (18%) | 17 (12%) |
Haematuria+proteinuria** | 8 (6%) | 5 (4%) |
Haematuria or proteinuria¶ | 40 (28%) | 28 (20%) |
Note 1: This table gives the number of patients (%) unless otherwise stated.
Note 2: The numbers with ‘haematuria only’, ‘proteinuria only’ and ‘haematuria+proteinuria’ do not always sum to the number with ‘haematuria or proteinuria’ due to missing data.
Note 3: Missing data.
*13 patients with missing data in the prednisolone group, 17 in the placebo group.
†9 patients with missing data in the prednisolone group, 12 in the placebo group.
‡11 patients with missing data in the prednisolone group, 9 in the placebo group.
§11 patients with missing data in the prednisolone group, 10 in the placebo group.
¶9 patients with missing data in the prednisolone group, 9 in the placebo group.
**8 patients with missing data in the prednisolone group, 8 in the placebo group.